Cargando…
(18)F‐FDG PET‐CT in a patient with methotrexate‐associated lymphoproliferative disorder
(18)F‐FDG PET‐CT clearly demonstrated the disease activity of MTX‐LPD. [Image: see text]
Autores principales: | Shimizu, Hayato, Nishioka, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763021/ https://www.ncbi.nlm.nih.gov/pubmed/29340266 http://dx.doi.org/10.1002/jgf2.145 |
Ejemplares similares
-
The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)
por: Watanabe, Shiro, et al.
Publicado: (2016) -
(18)F-FDG PET/CT in the Follow-Up of Mucosal Leishmaniasis
por: Camargo, Raphael A., et al.
Publicado: (2018) -
Fasting Hypoglycemia on (18)F-FDG PET/CT Scan
por: Nakayama, Michihiro, et al.
Publicado: (2017) -
FDG-PET/CT imaging parameters for predicting spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis
por: Kameda, Tomohiro, et al.
Publicado: (2022) -
(18)F-FDG PET/CT Findings in Cytomegalovirus Colitis
por: Kjaer, Anna Sophie L., et al.
Publicado: (2018)